For Penn
For Industry
PCI Ventures
Innovation at Penn
Info
Available Technologies
Browse Penn-owned technologies available for licensing.
HOME
SEARCH
RSS FEED
Search Results - covid-19
4
Results
Sort By:
Published Date
Title
ID
Descending
Ascending
Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering
A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy.Problem: Chimeric antigen receptor (CAR) T-cells...
Published: 5/4/2020
|
Inventor(s):
Margaret Billingsley
,
Carl June
,
Nathan Singh
,
Michael Mitchell
Keywords(s):
Bioengineering
,
COVID-19
,
Drug Delivery
,
Immunology
,
Immunotherapy
Category(s):
Therapeutics & Vaccines
Rapid method to design and screen novel lipid nanoparticles for mRNA delivery in vivo
A platform technology to rapidly identify novel lipid nanoparticle (LNP) formulations to carry mRNA-based therapeutics to target organs/cells in vivo.Problem: Messenger RNA (mRNA) has emerged as a promising new class of nucleic acid therapy, with the potential to induce protein production to treat and prevent a range of diseases. While significant progress...
Published: 5/4/2020
|
Inventor(s):
Michael Mitchell
,
Rui Zhang
,
Roman Spektor
Keywords(s):
Bioengineering
,
COVID-19
Category(s):
Chemical Processes and Synthesis
,
Research Tools & Reagents
,
Therapeutics & Vaccines
Improving drug delivery using red blood cell hitchhiking
Problem: A major challenge in drug delivery is ensuring that the drug reaches the target organ at a concentration sufficient to treat the disease. This is particularly problematic for acute illnesses of the vasculature, such as acute respiratory distress syndrome (ARDS), ischemic stroke, and myocardial infarction. In these diseases, patients are often...
Published: 2/13/2020
|
Inventor(s):
Jacob Brenner
,
Vladimir Muzykantov
Keywords(s):
COVID-19
Category(s):
Therapeutics & Vaccines
Repurposing of FDA-approved HER-inhibiting therapies for acute lung injury treatment
Mitigating ventilator-induced lung injury and acute respiratory distress syndrome through HER2/HER3 signaling pathway Problem: Acute lung injury, such as that induced by long-term treatment with a mechanical ventilator, and acute respiratory distress syndrome (ARDS) affects 190,000 patients per year in the United States, with associated mortality...
Published: 1/31/2020
|
Inventor(s):
Susan Margulies
Keywords(s):
COVID-19
Category(s):
Therapeutics & Vaccines
